Mehmet Fatih ORHAN

Scopus Publications

Serum immunoglobulins and lymphocyte subset levels and relation to treatment response in children with acute immune thrombocytopenia
Mehmet Cemal Dönmez, Mehmet Fatih Orhan, Öner Özdemir, Mustafa Büyükavcı
Trends in Pediatrics, 2026
Objective: In this study, we investigated the initial serum immunoglobulin and lymphocyte subset levels of children with immune thrombocytopenia (ITP), and their association with treatment response. Methods: Thirty children with ITP were retrospectively analyzed. Immunoglobulin isotypes, IgG subtypes, and lymphocyte subset levels in the patients were compared with those of the age- and sex-matched control group and age-appropriate reference values. In addition, we investigated the relationship between immunological parameters and treatment responses. Results: There was no statistically significant difference between the patient and control groups regarding immunoglobulin isotype and IgG subtype levels. However, IgG levels were below normal limits in 10 (33.3%) patients, and IgA and IgG2 levels were low in 2 patients with normal IgG levels. Younger age and low IgG level at diagnosis were associated with an increased treatment response on day 7. Conclusion: Serum immunoglobulin levels at the time of diagnosis can help predict treatment response in the early period and detect subclinical immunodeficiency in children with acute ITP.
Rituximab in pediatric B-cell Non-Hodgkin Lymphoma: Clinical outcomes and prognostic implications
Şefika Akyol, Turan Güzel, Alper Özcan, Serap Karaman, Mehmet Fatih Orhan, Veysiye Hülya Üzel, Mustafa Özay, Deniz Koçak Göl, Ebru Yılmaz, Baver Demir, Kamuran Karaman, Mustafa Büyükavcı, Musa Karakükcü, Ekrem Ünal
Trends in Pediatrics, 2025
Objective: B-cell Non-Hodgkin Lymphoma (B-NHL) is an aggressive malignancy in children requiring prompt multidisciplinary management. This retrospective cohort study aims to evaluate the clinical characteristics, treatment outcomes, and impact of rituximab (RTX) in pediatric B-NHL patients. Methods: We retrospectively analyzed 62 pediatric B-NHL patients treated at tertiary centers. Patient demographics, clinical presentation, histopathological subtypes, disease stage, treatment regimens, and survival outcomes were assessed. Event-free survival (EFS) and overall survival (OS) rates were analyzed based on lactate dehydrogenase (LDH) levels and RTX administration. Results: The mean age at diagnosis was 8.73±4.3 years, with a male predominance (79%). The most common histological subtype was Burkitt lymphoma (BL) (53.2%), followed by diffuse large B-cell lymphoma (DLBCL) (33.8%). Advanced-stage disease (III-IV) was observed in 74.1% of cases. RTX was administered in 72.5% of patients, with a mean of 5.1±2.7 doses. Febrile neutropenia (FEN) was noted in 74.1%, with intensive care unit (ICU) admission required for seven patients. Mortality was observed in 12 (19.3%) patients, including all patients with primary immunodeficiency (PID). The 5-year EFS for the entire cohort was 67.2%, and OS was 81.3%. Patients with LDH 400 U/L (EFS: 49.6%, OS: 70.7%; p=0.004 and p=0.015, respectively). In RTX-treated patients without PID, EFS was 76.5% versus 73.2% in those without RTX, but the difference was not statistically significant (p=0.53). Conclusions: Although not statistically significant, EFS was found to be higher in the RTX-treated group, suggesting that adding RTX to standard chemotherapy regimens may improve survival, particularly for high-risk patients, though its benefit in low-risk cases remains uncertain. Despite improved survival, patients with PID had poor outcomes, likely due to increased infections and disseminated disease. Risk-adapted, targeted treatment strategies are essential for optimizing outcomes in pediatric B-NHL. Further large-scale, randomized controlled trials are needed to confirm the efficacy of RTX in different risk groups and to optimize treatment regimens for pediatric B-NHL.
A Multicenter Retrospective Study Comparing Immunosuppressive Therapy Combined with Eltrombopag to Immunosuppressive Therapy Alone as Frontline Treatment for Pediatric Severe Aplastic Anemia
Didem Atay, Deniz Yılmaz Karapınar, Gonca Kaçar, Nihal Karadas, Hilmi Apak, Hasan Fatih Çakmaklı, Aysha Gadashova, Tekin Aksu, Tiraje Celkan, Neşe Yaralı, Mehmet Fatih Orhan, Alper Özcan, Mehmet Ertem, Selin Aytaç, Hale Ören, Sinan Akbayram, Melek Işık, Şebnem Yılmaz, Talia İleri, Mustafa Büyükavcı, Musa Karakükcü, Tuba Hilkay Karapınar, Fatih Erbey, İbrahim Eker, Davut Albayrak, Şule Ünal
Turkish Journal of Hematology, 2025
Objective: Eltrombopag (EPAG) added to standard immunosuppressive therapy (IST) has been associated with higher overall response (OR) and complete response (CR) rates in adult patients with treatment-naïve severe aplastic anemia (SAA), but clinical evidence on the efficacy of EPAG in children with acquired aplastic anemia is limited and controversial. This retrospective study aimed to determine the efficacy and safety of EPAG combined with IST in pediatric patients with SAA compared to a standard IST group. Materials and Methods: We compared the efficacy and safety of EPAG combined with IST (n=38) versus IST alone (n=57) as frontline treatment for pediatric patients with SAA. Results: The EPAG+IST group had higher CR and OR rates at 3 and 6 months, although the 1-year OR, CR, and partial response rates showed no significant difference between the two groups. Older age at diagnosis (>8.95 years) was associated with a higher OR rate at 6 months and 1 year in the EPAG+IST group (p=0.007 and p=0.005, respectively). The addition of EPAG to IST did not achieve superiority over IST alone in terms of overall survival (OS) and event-free survival (EFS) in this study, with 1-year EFS of 81.1% for EPAG+IST and 71.3% for IST, and 1-year OS of 89.2% versus 80.4%, respectively. Conclusion: EPAG+IST induced a faster response compared to IST alone without increasing toxic effects, but EPAG did not confer additional benefits regarding OS or relapse rates in children. Notably, older age at diagnosis was significantly associated with improved response rates in the EPAG+IST group.
Survey of Red Cell Transfusion Therapy and Immunohematology Services for Patients with Hemoglobinopathies in Türkiye
, Dilek Gürlek Gökçebay, Neslihan Andıç, Willy Albert Flegel
Turkish Journal of Hematology, 2025
Objective: Transfusion therapy is critical for many patients with β-thalassemia or sickle cell disease (SCD). We aimed to review current practices and document chronic transfusion therapy for patients with hemoglobinopathies in the transfusion service centers of Türkiye. Materials and Methods: A survey with 16 structured questions was distributed electronically to adult and pediatric hematologists in Türkiye. Responses were received from 37 centers across 18 cities, representing 1449 patients diagnosed with β-thalassemia major, β-thalassemia intermedia, and SCD. Results: Although 79% of centers reported performing extended red cell antigen typing prior to the first transfusion, adherence to national transfusion guidelines was inconsistent. Only 16% of centers routinely performed indirect antiglobulin testing before each transfusion despite guideline recommendations. Antibody identification capabilities varied, with 26% of centers lacking the capability onsite. Elution and adsorption testing were always performed at 13% of centers only, predominantly including university hospitals. Nearly half of the centers were always able to provide D, C, E, c, e, and Kell compatible red cell units, but one-fourth reported that they were unable to consistently provide compatible units due to limited supply. There was no access to red cell genotyping in the country. Conclusion: Our survey revealed disparities in transfusion practices and transfusion service laboratory infrastructure across Türkiye. There is a need for national policy initiatives to mandate adherence to national and international guidelines, expand immunohematology testing capabilities, and ensure the equitable distribution of phenotype-matched red cell units. These findings will contribute to discussions on establishing a centralized immunohematology reference laboratory and enabling red cell genotyping within the country to improve transfusion safety and health equity in hemoglobinopathy care.
Common viral respiratory infections in children with cancer during the COVID-19 pandemic: a multicenter study from Türkiye
Dilek Kaçar, Rejin Kebudi, Derya Özyörük, Deniz Tuğcu, Ayşenur Bahadır, Zeynep Canan Özdemir, Ali Aykan Özgüven, Mehmet Fatih Orhan, Ayşen Türedi Yıldırım, Canan Albayrak, İbrahim Kartal, Neriman Sarı, Hüseyin Tokgöz, Meryem Albayrak, Aylin Canbolat Ayhan, Nilgün Eroğlu, Sultan Aydın, Veysiye Hülya Üzel, Bülent Zülfikar, Ülkü Miray Yıldırım, Mustafa Büyükavcı, Hüseyin Gülen, Ersin Töret, Özcan Bör, Namık Yaşar Özbek, İnci Ergürhan İlhan, Neşe Yaralı
Turkish Journal of Pediatrics, 2024
Background. Microbiologic confirmation of respiratory tract infections gained importance during the coronavirus disease 2019 (COVID-19) pandemic. This study retrospectively evaluated seasonal distribution, clinical presentation, and complications of respiratory viral infections (RVIs) other than COVID-19 in children with cancer during and after the pandemic lockdown. Methods. Two hundred and sixty-five inpatient and outpatient RVI episodes in 219 pediatric cancer patients confirmed by multiplex reverse transcriptase polymerase chain reaction (RT-PCR) panels from 13 centers were enrolled. Results. Eighty-six (32.5%) of the total 265 episodes occurred in 16 months corresponding to the lockdowns in Türkiye, and the remaining 67.5% in 10 months thereafter. Human rhinovirus/enterovirus (hRE) (48.3%) was the most common agent detected during and after lockdown. Parainfluenza virus (PIV) (23.0%), influenza virus (9.8%), and respiratory syncytial virus (RSV) (9.1%) were the other common agents. The 28.7% of episodes were lower respiratory tract infections (LRTIs), and complications and mortality were higher than upper respiratory tract infections (URTIs) (25.0% vs 5.3%). Bacteremia was identified in 11.5% of culture-drawn episodes. Treatment delay in one-third and death within four weeks after RVI in 4.9% of episodes were observed. Conclusion. During the pandemic, fewer episodes of RVIs occurred during the lockdown period. Respiratory viruses may cause complications, delays in treatment, and even death in children with cancer. Therefore, increased awareness of RVIs and rapid detection of respiratory viruses will benefit the prevention and, in some cases, abrupt supportive and some antiviral treatment of RVI in children with cancer.
Identification of the molecular etiology in rare congenital hemolytic anemias using next-generation sequencing with exome-based copy number variant analysis
Esra Isik, Yesim Aydinok, Canan Albayrak, Basak Durmus, Zeynep Karakas, Mehmet Fatih Orhan, Nazan Sarper, Sultan Aydın, Selma Unal, Yesim Oymak, Nihal Karadas, Aysen Turedi, Davut Albayrak, Funda Tayfun, Deniz Tugcu, Serap Karaman, Mahmut Tobu, Ekrem Unal, Alper Ozcan, Sule Unal, Tekin Aksu, Aysegul Unuvar, Mustafa Bilici, Fatih Azik, Yilmaz Ay, Sema Aylan Gelen, Emine Zengin, Esin Albudak, Ibrahim Eker, Taner Karakaya, Ozgur Cogulu, Ferda Ozkinay, Tahir Atik
European Journal of Haematology, 2024
ObjectivesIn congenital hemolytic anemias (CHA), it is not always possible to determine the specific diagnosis by evaluating clinical findings and conventional laboratory tests. The aim of this study is to evaluate the utility of next‐generation sequencing (NGS) and clinical‐exome‐based copy number variant (CNV) analysis in patients with CHA.MethodsOne hundred and forty‐three CHA cases from 115 unrelated families referred for molecular analysis were enrolled in the study. Molecular analysis was performed using two different clinical exome panels in 130 patients, and whole‐exome sequencing in nine patients. Exome‐based CNV calling was incorporated into the traditional single‐nucleotide variant and small insertion/deletion analysis pipeline for NGS data in 92 cases. In four patients from the same family, the PK Gypsy variant was investigated using long‐range polymerase chain reaction.ResultsMolecular diagnosis was established in 86% of the study group. The most frequently mutated genes were SPTB (31.7%) and PKLR (28.5%). CNV analysis of 92 cases revealed that three patients had different sizes of large deletions in the SPTB and six patients had a deletion in the PKLR.ConclusionsIn this study, NGS provided a high molecular diagnostic rate in cases with rare CHA. Analysis of the CNVs contributed to the diagnostic success.
MYH9-related diseases in the differential diagnosis of chronic immune thrombocytopenic purpura
Simge Horoz Bicer, Mehmet Fatih Orhan
Marmara Medical Journal, 2024
Myosin heavy chain 9 (MYH9)-related platelet disorders (MYH9-RD) belong to the group of inherited thrombocytopenias characterized by giant platelets and Döhle bodies. The process leading to the diagnosis of MYH9-RD in a 13-year-old male patient, followed by the diagnosis of chronic immune thrombocytopenic purpura (ITP), is described. The patient had thrombocytopenia with increased mean platelet volume since he was a little boy. Low CD41, CD42 and CD61 levels were detected in blood tests sent to complete missing diagnostic tests. Platelet aggregation tests were also abnormal. The requested genetic test revealed a heterozygous mutation in the MYH9 gene. The patient’s audiogram and kidney functions were normal. In conclusion, because MYH9-RD appears to be rare, it is of great importance to maintain a high index of suspicion when managing patients diagnosed with chronic ITP. Additional complaints and findings should be considered at every outpatient clinic examination to make a more accurate diagnosis and prevent unnecessary treatments.
The Role of Ultrasonography in the Discrimination of Reactive Lymphadenopathy in Children
Elif Şeker Ekici, Mustafa Büyükavcı, Yasemin Gündüz, Mehmet Fatih Orhan, Bahri Elmas
Turk Osteoporoz Dergisi, 2024
Introduction: Many studies have been conducted on the role of ultrasonography in differentiating benign diseases that cause lymphadenopathy (LAP) from malignant diseases. However, there are no studies to distinguish LAP due to reactive etiologies from other benign infectious causes. In this study, the role of ultrasonography in the differentiation of benign LAPs was examined. Materials and Methods: This study prospectively evaluated 165 children with LAP aged 0-18 years. According to their clinical features, benign LAPs were grouped into viral and bacterial lymphadenitis, and reactive LAPs. Ultrasonographic characteristics of each group were assessed. Results: While loss of hilar echogenicity from ultrasonographic findings of LAPs was significant in differentiating reactive LAP from viral lymphadenitis, border irregularity was more favorable for bacterial lymphadenitis. Conclusion: Differentiating benign LAPs is important in the decision to prescribe antibiotics. In addition to the clinical features, ultrasonographic features can also be used to make this distinction.
The Relationship between Soluble Angiotensin-Converting Enzyme Level and Coronavirus Disease 2019 in Children: A Prospective Cohort Study
Hacer Efnan Melek Arsoy, Bahri Elmas, Ayşe Tarim, Pınar Dervişoğlu Çavdar, Mehmet Fatih Orhan, Hayrullah Yazar
Journal of Pediatric Infectious Diseases, 2024
Objective Our objective was to investigate soluble angiotensin-converting enzyme (sACE) levels in pediatric patients with coronavirus disease 2019 (COVID-19) and to identify factors associated with the occurrence and severity of pediatric COVID-19. Methods This was a prospective cohort study conducted between April 2020 and July 2020. The study population consisted of 143 children (between 1 month and 18 years old), 103 of whom had COVID-19 and 40 of whom were negative for COVID-19 (randomly selected). The sACE levels and other laboratory data of all participants were measured at admission (day 0, baseline). Repeat measurements were performed in patients on the 5th day. Disease severity was documented at baseline and on the 5th day, and the change in severity between these time points was recorded. Results Age and sex distribution were similar in the two groups. At baseline, 31 (30.1%) of the patients were asymptomatic, 58 (56.3%) had mild disease, and 14 (13.6%) had moderate disease. Baseline sACE levels were similar in the groups (p = 0.120). Higher weight was independently associated with low sACE levels in children (p = 0.037). The sACE level of patients on the 5th day was significantly lower compared with baseline (p = 0.007). Patients who experienced a decrease in disease severity were compared with those who did not demonstrate a decrease. Baseline sACE levels were significantly lower in those who experienced decreased severity (p = 0.039). Multiple linear regression revealed that COVID-19 severity at baseline was independently associated with the low sACE level at baseline (p = 0.023). Conclusion Lower sACE at diagnosis was associated with COVID-19 severity in children. However, no strong evidence was found that could suggest the sACE level as an important predictor for the occurrence or severity of COVID-19 in children.
Central nervous system thrombosis in pediatric acute lymphoblastic leukemia in Turkey: A multicenter study
Zeliha Guzelkucuk, Deniz Yılmaz Karapınar, Sema Aylan Gelen, Huseyin Tokgoz, Alper Ozcan, Yılmaz Ay, Aysenur Bahadır, Namik Yasar Ozbek, Ayse Ceyda Oren, Aylin Canbolat Ayhan, Arzu Akyay, Burcu Akıncı, Nihal Karadas, Aysegul Unuvar, Hale Oren, Ali Fettah, Zuhre Kaya, Bilgen Isık, İbrahim Eker, Serap Karaman, Aysen Turedi Yıldırım, Mehmet Fatih Orhan, Yesim Oymak, Cetin Timur, Nalan Yazici, Ayse Simsek, Neslihan Karakurt, Ersin Toret, Melike Sezgin Evim
Pediatric Blood and Cancer, 2023
BACKGROUND In patients with acute lymphoblastic leukemia (ALL), the risk of thromboembolism increases due to hemostatic changes secondary to the primary disease and due to treatment-related factors. In this multicenter study, we aimed to research the frequency of central nervous system (CNS) thrombosis occurring during treatment, hereditary and acquired risk factors, clinical and laboratory features of patients with thrombosis, treatment approaches, and thrombosis-related mortality and morbidity rates in pediatric ALL patients. PROCEDURE Pediatric patients who developed CNS thrombosis during ALL treatment from 2010 to 2021 were analyzed retrospectively in 25 different Pediatric Hematology Oncology centers in Türkiye. The demographic characteristics of the patients, symptoms associated with thrombosis, the stage of the leukemia treatment during thrombosis, the anticoagulant therapy applied for thrombosis, and the final status of the patients recorded through electronic medical records were determined. RESULTS Data from 70 patients with CNS thrombosis during treatment, out of 3968 pediatric patients with ALL, were reviewed. The incidence of CNS thrombosis was 1.8% (venous: 1.5 %; arterial: 0.03%). Among patients with CNS thrombosis, 47 had the event in the first 2 months. Low molecular weight heparin (LMWH) was the most commonly used treatment with a median of 6 months (min-max: 3-28 months). No treatment-related complications occurred. Chronic thrombosis findings occurred in four patients (6%). In five (7%) patients who developed cerebral vein thrombosis, neurological sequelae (epilepsy and neurological deficit) remained. One patient died related to thrombosis, and the mortality rate was 1.4%. CONCLUSION Cerebral venous thrombosis and, less frequently, cerebral arterial thrombosis may develop in patients with ALL. The incidence of CNS thrombosis is higher during induction therapy than during other courses of treatment. Therefore, patients receiving induction therapy should be monitored carefully for clinical findings suggestive of CNS thrombosis.
The effect of early and long-term propranolol therapy on learning and memory in mice
Mehmet Fatih Orhan, Pelin Tanyeri, Mehmet Emin Büyükokuroğlu, Mustafa Büyükavci
Behavioural Pharmacology, 2023
Evaluation of Lymphocyte Subgroups in Children with Glucose-6-Phosphate Dehydrogenase Deficiency
Mehmet Fatih Orhan, , Olena Erkun, Oner Ozdemir, Mustafa Buyukavci, , , and
Turkish Archives of Pediatrics, 2023
Intravenous Iron Therapy for Children with Iron Deficiency Anemia
Mehmet F. Orhan, Mustafa Büyükavci
Journal of Pediatric Hematology Oncology, 2023
Different Phenotypes of a New Mutation: Two Siblings with ADA-2 Deficiency Presenting with Anemia and Neutropenia (Case Reports and Literature Review)
Öner Özdemır, Mehmet Fatih Orhan, Mustafa Büyükavcı, Emine Aylin Yılmaz, Orhan Görükmez
Asthma Allergy Immunology, 2023
A Decision Support System For Detecting Stage In Hodgkin Lymphoma Patients Using Artificial Neural Network and Optimization Algorithms
Sakarya University Journal of Computer and Information Sciences, 2022
Major and minor subgroup profile of blood in patients receiving multiple transfusions and donors
MehmetFatih Orhan, MervePilavci Adigül, Mustafa Altindiş, Mehmet Köroğlu
Asian Journal of Transfusion Science, 2022
Acquired Thrombotic Thrombocytopenic Purpura in a 5-Year-old Child with Wiskott-Aldrich Syndrome
Öner Özdemir, Mehmet Fatih Orhan, Mustafa Büyükavcı, Orhan Görükmez
Journal of Pediatric Hematology Oncology, 2022
10-year Survival Analysis of Pediatric Hematology and Oncology in Turkey
Mehmet Fatih Orhan
Guncel Pediatri, 2022
A FLOW CYTOMETRIC EVALUATION OF B LYMPHOCYTE CELLS AND SUBGROUPS OF CHILDREN DIAGNOSED WITH COVID-19
Mehmet Orhan, Öner Özdemir, Gülay Trak
Istanbul Tip Fakultesi Dergisi, 2022
Epidural blockade for alternative management of priapism: A case report of child with T-cell acute lymphoblastic leukemia
Ahmet Gokce, Deniz Gul, Mehmet Fatih Orhan, Mustafa Büyükavci, Gurkan Demir, Serbulent Gokhan Beyaz
Urology, 2021
Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
Sheena Mukkada, Nickhill Bhakta, Guillermo L Chantada, Yichen Chen, Yuvanesh Vedaraju, Lane Faughnan, Maysam R Homsi, Hilmarie Muniz-Talavera, Radhikesh Ranadive, Monika Metzger, Paola Friedrich, Asya Agulnik, Sima Jeha, Catherine Lam, Rashmi Dalvi, Laila Hessissen, Daniel C Moreira, Victor M Santana, Michael Sullivan, Eric Bouffet, Miguela A Caniza, Meenakshi Devidas, Kathy Pritchard-Jones, Carlos Rodriguez-Galindo, A Juan Ribelles, Adriana Balduzzi, Alaa Elhaddad, Alejandra Casanovas, Alejandra Garcia Velazquez, Aliaksandra Laptsevich, Alicia Chang, Alessandra Lamenha F. Sampaio, Almudena González Prieto, Alvaro Lassaletta, Amaranto Suarez M, Ana Patricia Alcasabas, Anca Colita, Andres Morales La Madrid, Angélica Samudio, Annalisa Tondo, Antonella Colombini, Antonis Kattamis, N Araceli Lopez Facundo, Arpita Bhattacharyya, Aurélia Alimi, Aurélie Phulpin, Barbora Vakrmanova, Basak A Aksoy, Benoit Brethon, Jator Brian Kobuin, Carla Nolasco Monteiro, Catherine Paillard, Catherine Vezina, Bozkurt Ceyhun, Cristiana Hentea, Cristina Meazza, Daniel Ortiz-Morales, Roque Daniel Solorzano, Daniela Arce Cabrera, Daniele Zama, Debjani Ghosh, Diana Ramírez-Rivera, Doris A Calle Jara, Dragana Janic, Elianneth Rey Helo, Elodie Gouache, Enmanuel Guerrero Quiroz, Enrique Lopez, Eric Thebault, Essy Maradiegue, Eva de Berranger, Fatma S E Ebeid, Federica Galaverna, Federico Antillon-Klussmann, Felipe Espinoza Chacur, Fernando Daniel Negro, Francesca Carraro, Francesca Compagno, Francisco Barriga, Gabriela Tamayo Pedraza, Gissela Sanchez Fernandez, Gita Naidu, Gülnur Tokuc, Hamidah Alias, Hannah Grace B Segocio, Houda Boudiaf, Imelda Asetre Luna, Iris Maia, Itziar Astigarraga, Ivan Maza, Jacqueline E Montoya Vásquez, Janez Jazbec, Jelena Lazic, Jeniffer Beck Dean, Jeremie Rouger-Gaudichon, Johanny Carolina Contreras González, Jorge Huerta Aragonés, José L Fuster, Juan Quintana, Julia Palma, Karel Svojgr, Karina Quintero, Karolina Malic Tudor, Kleopatra Georgantzi, Kris Ann P Schultz, Laura Ureña Horno, Lidia Fraquelli, Linda Meneghello, Lobna Shalaby, Lola L Macias Mora, Lorna A Renner, Luciana Nunes Silva, Luisa Sisinni, Mahmoud Hammad, M Fernández Sanmartín, C Marcela Zubieta A, María Constanza Drozdowski, Maria Kourti, Marcela María Palladino, Maria R Miranda Madrazo, Marilyne Poiree, Marina Popova, Mario Melgar, Marta Baragaño, Martha J Avilés-Robles, Massimo Provenzi, Mecneide Mendes Lins, Mehmet Fatih Orhan, Milena Villarroel, Mónica Jerónimo, Mónica Varas Palma, Muhammad Rafie Raza, Mulindwa M Justin, Najma Shaheen, Nerea Domínguez-Pinilla, Nicholas S Whipple, Nicolas André, Ondrej Hrusak, Pablo Velasco Puyó, Pamela Zacasa Vargas, Paola Olate Mellado, Pascale Yola Gassant, Paulina Diaz Romero, Raffaella De Santis, Rejin Kebudi, Riza Boranbayeva, Roberto Vasquez, Romel A. Segura, Roy Enrique Rosado, Sandra Gómez, Sandra Raimbault, Sanjeeva Gunasekera, Sara M Makkeyah, Sema Buyukkapu Bay, Sergio M Gómez, Séverine Bouttefroy, Shahnoor Islam, Sherif Abouelnaga, Silvio Fabio Torres, Simone Cesaro, Sofia Nunes, Soraia Rouxinol, Sucharita Bhaumik, Symbat Saliyeva, Tamara Inostroza, Thelma Velasquez, Tint Myo Hnin, Ulrika Norén-Nyström, Valentina Baretta, Yajaira Valentine Jimenez-Antolinez, Vanesa Pérez Alonso, Vanessa Ayer Miller, Virginie Gandemer, Viviana Lotero, Volha Mishkova, Wendy Gómez-García, Yeva Margaryan, Yumna Syed
Lancet Oncology, 2021
COVID-19 infection in children with cancer and stem cell transplant recipients in Turkey: A nationwide study
Rejin Kebudi, Nilgün Kurucu, Deniz Tuğcu, Şadan Hacısalihoğlu, Tunç Fışgın, Süheyla Ocak, Gülnur Tokuç, Gül Nihal Özdemir, Ceyhun Bozkurt, Dilek İnce, Seda Aras, Ali Ayçiçek, Başak Adaklı Aksoy, Nihal Karadaş, Gülyüz Öztürk, Mehmet Fatih Orhan, Eda Ataseven, Sinan Akbayram, Ebru Yılmaz, Özlem Tüfekçi, Sema Vural, Arzu Akyay, Aylin Canbolat Ayhan, Suar Kılıç, Veysiye Hülya Uzel, Yeter Düzenli, Elif Güler Kazancı, Can Acıpayam, Murat Elli, Atilla Tanyeli, Zeynep Karakas, Ayper Somer, Ateş Kara
Pediatric Blood and Cancer, 2021
Evaluation of taste and smell disorders in pediatric COVID-19 Cases
Bahri Elmas, Pınar Derviʂoğlu Çavdaroğlu, Mehmet Fatih Orhan, Gizem Ay, Ibrahim Caner, Ayʂe Tarım, Ömer Faruk Ateʂ, Hande Toptan
Revista Da Associacao Medica Brasileira, 2021
Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study
Emine Zengin, Nazan Sarper, Arzu Yazal Erdem, Işık Odaman Al, Melike Sezgin Evim, Neşe Yaralı, Burcu Belen, Arzu Akçay, Ayşen Yıldırım, Tuba Hilkay Karapınar, Adalet Meral Güneş, Sema Aylan Gelen, Hale Ören, Lale Olcay, Birol Baytan, Hüseyin Gülen, Gülyüz Öztürk, Mehmet Fatih Orhan, Yeşim Oymak, Sibel Akpınar, Özlem Tüfekçi, Meryem Albayrak, Burçak Tatlı Güneş, Aylin Canpolat, Namık Özbek
Turkish Journal of Hematology, 2021
Shiga toxin-Associated hemolytic uremic syndrome and unexpected course
Hakan Erdoğan, Gökçe Nur Aşkın, Şenay Mengi, Nevin Kılıç, Mehmet Fatih Orhan
Turkish Nephrology Dialysis and Transplantation Journal, 2018
Platelet function alterations and their relation to P-selectin (CD62P) expression in children with iron deficiency anemia
Zuhal K Yldrm, Mehmet F Orhan, Mustafa Büyükavc
Blood Coagulation and Fibrinolysis, 2011
Undiagnosed cardiac abnormalities among school-aged children
Guncel Pediatri, 2010
A case of heliotrope rash associated with acetylsalicylic acid
Erciyes Tip Dergisi, 2009
Spontaneous bleeding from external ear canal as a presenting symptom in a child with von Willebrand disease
Mustafa Buyukavci, Mehmet Fatih Orhan
International Journal of Pediatric Otorhinolaryngology Extra, 2007
Severe congenital factor X deficiency with intracranial bleeding in two siblings
Bahri Ermis, Rahmi Ors, Ayhan Tastekin, Fatih Orhan
Brain and Development, 2004

Mehmet Fatih ORHAN

EDUCATION

RESEARCH INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS